Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of undertakings from 7 shareholders to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company's capital and voting rights by them.
Considering the 85.6% of the capital that will be acquired by Zydus Lifesciences Limited from PAI Partners, the management of Amplitude Surgical and two minority shareholders, Zydus Lifesciences Limited will be in a position with these undertakings to acquire more than 90% of the capital and voting rights of Amplitude Surgical at the end of the tender offer.
These undertakings to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company's capital and voting rights, may be revoked in the event of a competing tender offer being filed by a third party, declared compliant and opened by the Autorité des marchés financiers.
The acquisition of the 85.6% block is expected to be completed by June 2025 and the draft tender offer will be filed with the Autorité des marchés financiers upon receipt of regulatory approvals. The opening of the tender offer will then be subject to the clearance decision of the Autorité des marchés financiers.
Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 831.40 as compared to the previous close of Rs. 822.10. The total number of shares traded during the day was 377278 in over 12806 trades.
The stock hit an intraday high of Rs. 840.00 and intraday low of 816.00. The net turnover during the day was Rs. 312702461.00.